PCML
CPRX

Pavaki Capital Management LLC’s Catalyst Pharmaceutical CPRX Stock Holding History

Pavaki Capital Management LLC’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$251K Hold
8,000
– – 0.09% 119
2026
Q1 		$198K Hold
8,000
– – 0.08% 123
2025
Q4 		$187K Buy
+8,000
New +$178K 0.07% 108

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
CIEC
Crédit Industriel et Commercial Paris France, France $1.55B AUM 42.08% 1-Year Est. Return

Pavaki Capital Management LLC's CPRX Position: Q2 2026 in Review

Pavaki Capital Management LLC held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 8,000 shares worth $251K. The position accounts for 0.09% of the portfolio, ranked #119.

Pavaki Capital Management LLC first reported a position in CPRX in Q4 2025 and has held it in 3 quarters since. 166 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Pavaki Capital Management LLC held 8,000 shares of Catalyst Pharmaceutical worth $251K as of Q2 2026.
  • Pavaki Capital Management LLC left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
  • Catalyst Pharmaceutical made up 0.09% of Pavaki Capital Management LLC's portfolio in Q2 2026, its #119 holding.
  • Pavaki Capital Management LLC first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
  • 166 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q2 2026, filed 7 Aug 2026.